FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT FDA Downgrades Foreign Inspections: Book
06/19/2019
 
 
TXT Sharpless Wants to be Nominated for Commissioner
06/21/2019
 
 
TXT Shuren Discusses Device Reporting Changes
06/21/2019
 
 
TXT Woodcock Urges Changes to Petitions, 180-day Exclusivity
06/19/2019
 
 
TXT Aclaris Video Misbrands Eskata: FDA
06/20/2019
 
 
TXT Comments on FDA Benefit/Risk Assessment Framework
06/19/2019
 
 
TXT DTC Oncology Indication Study
06/20/2019
 
 
TXT FDA Developing Peptide Evaluation Tools
06/19/2019
 
 
TXT Imarc Details BIMO Findings
06/19/2019
 
 
TXT Lawmakers Urge Justice Dept. to Go After Generic Firms
06/17/2019
 
 
TXT Latest Federal Register Notices
06/23/2019
 
 
TXT Product Approval Summaries
06/23/2019
 
 
TXT Since Our Last Issue ...
06/23/2019
 
 
TXT Guide on Submitting Promo Labeling/Ad Materials
06/21/2019
 
 
TXT Opioid Benefit/Risk Framework Guidance
06/20/2019
 
 
TXT Grassley Opposes ‘International Pricing Index’ for Drug Prices
06/20/2019
 
 
TXT GE Healthcare Recalls Infant Warmers
06/19/2019
 
 
TXT Compounding Pharmacists See FDA ’Overreach’
06/19/2019
 
 
TXT Companies on Bispecific Antibody Development
06/19/2019
 
 
TXT Multiple Dietary Supplement Violations at PRL
06/18/2019
 
 
TXT FDA Enhances Paragraph 4 Patent List
06/18/2019
 
 
TXT Generics Lobby Backs China Tariff Drug Exclusion
06/18/2019
 
 
TXT Drug and Bio Development Times Similar: Analysis
06/18/2019
 
 
TXT CGMP Violations at Tropical Seas
06/18/2019
 
 
TXT Cook Recalls Advance Enforcer Balloon Catheter
06/18/2019
 
 
TXT Latest FDA Warning Letters
06/18/2019
 
 
TXT Cybersecurity Threat Issued on BD Alaris Gateway
06/17/2019
 
 
TXT 1/2 of FDA-Required Post Marketing Studies Get Published
06/17/2019
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving